EXCEED THE SPACE PROVIDED. The two major research directions for the Division of Hematology at Stanford are malignant hematology and vascular biology. This involvesboth basic and clinical research. The.program described herein will train postdoctoral fellows for a career in academic hematology. Candidates with MD or MD/PnD degrees who have completed training in Internal Medicine will be admitted to the three-year program. The first year of the program consists of an intensive training in clinical hematology,including benign and malignant hematology, stem cell and bone marrow transplantation, and transfusion medicine. In Year 2 and Year 3, the trainees will devote the majority of their time to research-based study. This will be done in a Basic-Scientist Pathway or a Clinical Investigator Pathway. The Basic Scientist Pathwayis primarily for trainees with substantialprior basic research experience, focusing on malignanthematology,vascularbiology and related basic research areas, The Clinical Investigator Pathway provides formal training in clinical research and incorporates the K30 Clinical Investigator Training program at Stanford under the direction of Dr. Mark Hlatky, leading to a Master's degree at the completion of formal training. In addition to the didactictraining, the Clinical Investigator Pathway fellow will also conduct hands-on clinical trials in the Division of Hematology. Fellow stipend support for the research training in Year 2 and Year 3 is requested in this grant application.More than three years of trainingis often required. Trainees are encouraged to apply for and obtain their own independentmentored research training support (K08 or K23) in Year 4. For each fellow, the research training will be supervised by a full-time faculty member in the Division of Hematology, or one of a numberof associate faculty members at Stanford University, representing disciplines relevant to hematology training. These include faculty in biochemistry, molecular pharmacology, microbiology, immunology, pathology, medical oncology, bone marrow transplantation, cardiology, pediatrics, epidemiology, outcome research and health policy. The progress of each fellow will be reviewed by the Program Director and the Training Program Steering Committee. At the conclusion of their training,trainees will be prepared for a career in academic hematology, as an independentinvestigator at the forefront of science and hematology. 'ERFORMANCE SITE(S) (organization, city, state) Stanford University School of Medicine, Palo Alto Veterans' Affairs Health Care System, Lucille Packard Children's Hospital KEY PERSONNEL ========================================Section End===========================================

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
5T32HL007970-05
Application #
6906461
Study Section
Special Emphasis Panel (ZHL1-CSR-M (F1))
Program Officer
Chang, Henry
Project Start
2001-08-27
Project End
2006-07-31
Budget Start
2005-08-01
Budget End
2006-07-31
Support Year
5
Fiscal Year
2005
Total Cost
$49,539
Indirect Cost
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Goueli, Basem S; Powell, Marianne Broome; Finger, Elizabeth C et al. (2012) TBC1D16 is a Rab4A GTPase activating protein that regulates receptor recycling and EGF receptor signaling. Proc Natl Acad Sci U S A 109:15787-92
Lee, Carolyn S; Ungewickell, Alexander; Bhaduri, Aparna et al. (2012) Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts. Blood 120:3288-97
Oh, Stephen T; Simonds, Erin F; Jones, Carol et al. (2010) Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 116:988-92
Chao, Mark P; Alizadeh, Ash A; Tang, Chad et al. (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142:699-713
Bluestone, J A; Liu, W; Yabu, J M et al. (2008) The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 8:2086-96
Kao, Jelena M; McMillan, Alex; Greenberg, Peter L (2008) International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 83:765-70